NASDAQ:SIGA

SIGA Technologies Competitors

$7.10
+0.04 (+0.57 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.01
Now: $7.10
$7.18
50-Day Range
$6.32
MA: $6.65
$7.15
52-Week Range
$5.25
Now: $7.10
$8.10
Volume282,283 shs
Average Volume267,333 shs
Market Capitalization$544.91 million
P/E Ratio17.75
Dividend YieldN/A
Beta0.53

Competitors

SIGA Technologies (NASDAQ:SIGA) Vs. IGMS, RVNC, DRNA, AXSM, NGM, and MORF

Should you be buying SIGA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to SIGA Technologies, including IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), and Morphic (MORF).

IGM Biosciences (NASDAQ:IGMS) and SIGA Technologies (NASDAQ:SIGA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Risk & Volatility

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares IGM Biosciences and SIGA Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than IGM Biosciences.

Analyst Ratings

This is a breakdown of current recommendations and price targets for IGM Biosciences and SIGA Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
SIGA Technologies0000N/A

IGM Biosciences currently has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' higher possible upside, equities analysts clearly believe IGM Biosciences is more favorable than SIGA Technologies.

Profitability

This table compares IGM Biosciences and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
SIGA Technologies34.62%37.31%25.33%

Summary

SIGA Technologies beats IGM Biosciences on 7 of the 11 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and SIGA Technologies (NASDAQ:SIGA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Revance Therapeutics and SIGA Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than Revance Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Revance Therapeutics and SIGA Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00503.00
SIGA Technologies0000N/A

Revance Therapeutics currently has a consensus target price of $36.40, indicating a potential upside of 29.40%. Given Revance Therapeutics' higher possible upside, research analysts clearly believe Revance Therapeutics is more favorable than SIGA Technologies.

Profitability

This table compares Revance Therapeutics and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
SIGA Technologies34.62%37.31%25.33%

Dicerna Pharmaceuticals (NASDAQ:DRNA) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and SIGA Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than Dicerna Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Dicerna Pharmaceuticals and SIGA Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
SIGA Technologies0000N/A

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, indicating a potential upside of 45.01%. Given Dicerna Pharmaceuticals' higher possible upside, research analysts clearly believe Dicerna Pharmaceuticals is more favorable than SIGA Technologies.

Profitability

This table compares Dicerna Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
SIGA Technologies34.62%37.31%25.33%

Axsome Therapeutics (NASDAQ:AXSM) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Axsome Therapeutics and SIGA Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than Axsome Therapeutics.

Institutional and Insider Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Axsome Therapeutics and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
SIGA Technologies34.62%37.31%25.33%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Axsome Therapeutics and SIGA Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
SIGA Technologies0000N/A

Axsome Therapeutics currently has a consensus target price of $146.90, indicating a potential upside of 177.22%. Given Axsome Therapeutics' higher possible upside, research analysts clearly believe Axsome Therapeutics is more favorable than SIGA Technologies.

Summary

SIGA Technologies beats Axsome Therapeutics on 6 of the 11 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and SIGA Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has lower revenue, but higher earnings than NGM Biopharmaceuticals.

Institutional & Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NGM Biopharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
SIGA Technologies34.62%37.31%25.33%

Analyst Ratings

This is a summary of current ratings and price targets for NGM Biopharmaceuticals and SIGA Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
SIGA Technologies0000N/A

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, indicating a potential upside of 53.80%. Given NGM Biopharmaceuticals' higher possible upside, analysts plainly believe NGM Biopharmaceuticals is more favorable than SIGA Technologies.

Summary

NGM Biopharmaceuticals beats SIGA Technologies on 7 of the 13 factors compared between the two stocks.

Morphic (NASDAQ:MORF) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Morphic has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Morphic and SIGA Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06
SIGA Technologies$26.74 million20.38$-7,240,000.00N/AN/A

SIGA Technologies has higher revenue and earnings than Morphic.

Institutional & Insider Ownership

61.5% of Morphic shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 39.5% of Morphic shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Morphic and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphicN/A-36.62%-20.69%
SIGA Technologies34.62%37.31%25.33%

Analyst Ratings

This is a summary of current ratings and price targets for Morphic and SIGA Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Morphic00203.00
SIGA Technologies0000N/A

Morphic presently has a consensus target price of $63.3333, indicating a potential upside of 6.71%. Given Morphic's higher possible upside, analysts plainly believe Morphic is more favorable than SIGA Technologies.


SIGA Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49+16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13+1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09+1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99+2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43+3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35+3.0%$1.93 billion$16.98 million-38.04Insider Selling
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57+0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58+0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16+1.3%$1.87 billion$64.19 million-9.96
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96+2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94+0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93+21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16+0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57+1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57+1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99+7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15+1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26+6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19+1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80+1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32+0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61+1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41+13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20+5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28+0.3%$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74+5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60+4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56+3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96+0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88+0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31+0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30+2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19+5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00+1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20+1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80+1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16+4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95+3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62+3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84+0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80+3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35+2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51+1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90+7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69+2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49+0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70+1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39+2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.